Related Experiment Videos
Bronchial secretion concentrations of tobramycin
The American Review of Respiratory Disease
|February 1, 1982
Summary
Lung infections significantly increase tobramycin concentrations in bronchial secretions, nearly doubling levels compared to healthy patients. This suggests infections enhance drug accumulation in the lungs.
Area of Science:
- Pharmacokinetics
- Infectious Diseases
- Respiratory Medicine
Background:
- Tobramycin is an aminoglycoside antibiotic used to treat bacterial infections.
- Understanding drug distribution in infected tissues is crucial for optimizing treatment efficacy.
- Pneumonia can alter the physiological environment of the lungs, potentially affecting drug concentrations.
Purpose of the Study:
- To investigate the effect of lung infection on tobramycin concentrations in bronchial secretions.
- To compare tobramycin levels in bronchial secretions of patients with and without pneumonia.
Main Methods:
- Bronchial secretions and serum samples were collected from patients.
- Tobramycin concentrations were measured in both sample types.
- Data were analyzed to compare concentrations between infected and non-infected lung groups.
Main Results:
- Mean tobramycin concentrations in bronchial secretions were approximately two times higher in patients with pneumonia compared to those without.
- The mean tobramycin bronchial secretion to serum concentration ratio was significantly higher in infected lungs (0.66) than in non-infected lungs (0.17).
Conclusions:
- Lung infection appears to enhance the accumulation of tobramycin in bronchial secretions.
- These findings suggest that pneumonia may increase local tobramycin concentrations, potentially impacting treatment effectiveness.